News & Media
SK life science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK life science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
9/12/2022
Expert Consensus Opinions Published in Neurology and Therapy Discuss Adjustment of Anti-Seizure Medication Dosing for Optimal Care
Full release8/09/2022
New Drug Filing for Cenobamate Accepted for Review in Canada and Israel
Full release7/14/2022
SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America
Full release7/13/2022
SK Biopharmaceuticals’ 2022 Sustainability Report Reinforces its Commitment to ESG Management
Full release6/22/2022
Long-Term Efficacy and Safety Data of XCOPRI® (cenobamate tablets) CV Published in Neurology
Full release5/25/2022
SK Biopharmaceuticals Announces Social Value Performance for 2021
Full release5/19/2022
SK Biopharmaceuticals Partners with Cala to Fuel Innovation in Neurology
Full release3/31/2022
SK life science Presents Long-term Data on Cognitive and Psychiatric Adverse Events Associated with XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AAN 2022 Annual Meeting
Full release3/23/2022
SK life science to Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting
Full release2/24/2022
SK Biopharmaceuticals Becomes First Korean Company to Join Pharmaceutical Supply Chain Initiative
Full release